Detalles de la búsqueda
1.
Effect of smoking status on lung function, patient-reported outcomes, and safety among COPD patients treated with glycopyrrolate inhalation powder: pooled analysis of GEM1 and GEM2 studies.
Respir Res;
20(1): 135, 2019 Jul 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-31266489
2.
Evaluation of systemic absorption and bronchodilator effect of glycopyrronium bromide delivered by nebulizer or a dry powder inhaler in subjects with chronic obstructive pulmonary disease.
Respir Res;
20(1): 132, 2019 Jun 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-31253162
3.
Efficacy of Indacaterol/Glycopyrrolate in Patients with COPD by Airway Reversibility at Baseline: A Pooled Analysis of the FLIGHT1 and FLIGHT2 12-Week Studies.
COPD;
16(2): 133-139, 2019 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-31242792
4.
Dose selection for glycopyrrolate/eFlow® phase III clinical studies: results from GOLDEN (Glycopyrrolate for Obstructive Lung Disease via Electronic Nebulizer) phase II dose-finding studies.
Respir Res;
18(1): 202, 2017 12 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-29202767
5.
Dual Bronchodilation with Indacaterol Maleate/Glycopyrronium Bromide Compared with Umeclidinium Bromide/Vilanterol in Patients with Moderate-to-Severe COPD: Results from Two Randomized, Controlled, Cross-over Studies.
Lung;
195(6): 739-747, 2017 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-28993871
6.
Implementing Digital Technologies in Clinical Trials: Lessons Learned.
Innov Clin Neurosci;
19(4-6): 65-69, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35958972
7.
Improvement in Lung Function and Patient-Reported Outcomes in Patients with COPD with Comorbid Anxiety and Depression Receiving Nebulized Glycopyrrolate in the GOLDEN 3 and 4 Studies.
Int J Chron Obstruct Pulmon Dis;
16: 865-875, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-33833507
8.
The in vitro effects of Xancor, a synthetic astaxanthine derivative, on hemostatic biomarkers in aspirin-naïve and aspirin-treated subjects with multiple risk factors for vascular disease.
Am J Ther;
17(2): 125-32, 2010.
Artículo
en Inglés
| MEDLINE | ID: mdl-20305399
9.
The Effect of Baseline Rescue Medication Use on Efficacy and Safety of Nebulized Glycopyrrolate Treatment in Patients with COPD from the GOLDEN 3 and 4 Studies.
Int J Chron Obstruct Pulmon Dis;
15: 745-754, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-32341641
10.
Effect of Gender on Lung Function and Patient-Reported Outcomes in Patients with COPD Receiving Nebulized Glycopyrrolate.
Int J Chron Obstruct Pulmon Dis;
15: 995-1004, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-32440111
11.
The Effect of Metabolic Syndrome Status on Lung Function and Patient-reported Outcomes in Patients with COPD Receiving Nebulized Glycopyrrolate.
Chronic Obstr Pulm Dis;
7(4): 315-326, 2020 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-32822528
12.
Efficacy and safety of a novel, nebulized glycopyrrolate for the treatment of COPD: effect of baseline disease severity and age; pooled analysis of GOLDEN 3 and GOLDEN 4.
Int J Chron Obstruct Pulmon Dis;
14: 27-37, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-30587959
13.
Effect of smoking status on lung function, patient-reported outcomes, and safety among patients with COPD treated with indacaterol/glycopyrrolate: Pooled analysis of the FLIGHT1 and FLIGHT2 studies.
Respir Med;
155: 113-120, 2019 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-31344660
14.
Efficacy and safety of glycopyrrolate in patients with COPD by reversibility: pooled analysis of GEM1 and GEM2 12-week studies.
Int J Chron Obstruct Pulmon Dis;
14: 461-470, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-30863047
15.
Efficacy and Safety of Nebulized Glycopyrrolate/eFlow® Closed System in Patients with Moderate-to-Very-Severe Chronic Obstructive Pulmonary Disease with Pre-Existing Cardiovascular Risk Factors.
Chronic Obstr Pulm Dis;
6(1): 86-99, 2018 Dec 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-30775427
16.
Effect of background long-acting beta2-agonist therapy on the efficacy and safety of a novel, nebulized glycopyrrolate in subjects with moderate-to-very-severe COPD.
Int J Chron Obstruct Pulmon Dis;
13: 2917-2929, 2018.
Artículo
en Inglés
| MEDLINE | ID: mdl-30275690
17.
In Vitro Characterization of the eFlow Closed System Nebulizer with Glycopyrrolate Inhalation Solution.
J Aerosol Med Pulm Drug Deliv;
31(3): 162-169, 2018 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-29125918
18.
Long-term safety of glycopyrrolate/eFlow® CS in moderate-to-very-severe COPD: Results from the Glycopyrrolate for Obstructive Lung Disease via Electronic Nebulizer (GOLDEN) 5 randomized study.
Respir Med;
132: 251-260, 2017 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-28919143
19.
Efficacy and safety of glycopyrrolate/eFlow® CS (nebulized glycopyrrolate) in moderate-to-very-severe COPD: Results from the glycopyrrolate for obstructive lung disease via electronic nebulizer (GOLDEN) 3 and 4 randomized controlled trials.
Respir Med;
132: 238-250, 2017 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-28838685
20.
Safety and pharmacokinetic effects of TNP-470, an angiogenesis inhibitor, combined with paclitaxel in patients with solid tumors: evidence for activity in non-small-cell lung cancer.
J Clin Oncol;
20(22): 4440-7, 2002 Nov 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-12431966